Search Results - "Ekoka Omoruyi, Edmund V"

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

    Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years by Burmester, Gerd R, Gottenberg, Jacques-Eric, Caporali, Roberto, Winthrop, Kevin L, Tanaka, Yoshiya, Ekoka Omoruyi, Edmund V, Rajendran, Vijay, Van Hoek, Paul, Van Beneden, Katrien, Takeuchi, Tsutomu, Westhovens, René, Aletaha, Daniel

    Published in Annals of the rheumatic diseases (23-05-2024)
    “…To update the long-term safety profile of filgotinib, a Janus kinase-1 preferential inhibitor, in patients with moderate-to-severe rheumatoid arthritis. Data…”
    Get more information
    Journal Article
    Save to List
    Saved in:
  2. 2
    Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

    Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study by Buch, Maya H, Aletaha, Daniel, Combe, Bernard G, Tanaka, Yoshiya, Caporali, Roberto, Schulze-Koops, Hendrik, Takeuchi, Tsutomu, Gottenberg, Jacques-Eric, Blanco, Ricardo, Verschueren, Patrick, Zubrzycka-Sienkiewicz, Anna, De Leonardis, Francesco, Ekoka Omoruyi, Edmund V, Rajendran, Vijay, Emery, Paul

    Published in Rheumatic & musculoskeletal diseases open (24-10-2024)
    “…Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate

    Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate by Buch, Maya H, Walker, David, Edwards, Christopher J, Barry, Jane, Akroyd, Laura, Omoruyi, Edmund V Ekoka, Taylor, Peter C

    Published in Rheumatology (Oxford, England) (27-09-2024)
    “…Clinical trials restricted to moderately active RA are limited. Filgotinib is approved for treating moderate to severe active RA. This post hoc analysis…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    P117 Efficacy of filgotinib in patients with rheumatoid arthritis: Week 156 results from a long-term extension study

    P117 Efficacy of filgotinib in patients with rheumatoid arthritis: Week 156 results from a long-term extension study by Buch, Maya H, Aletaha, Daniel, Caporali, Roberto, Combe, Bernard, Schulze-Koops, Hendrik, Gottenberg, Jacques-Eric, Tanaka, Yoshiya, Blanco, Ricardo, Takeuchi, Tsutomu, Omoruyi, Edmund V Ekoka, Van Beneden, Katrien, Rajendran, Vijay, Watson, Chris, De Leonardis, Francesco, Emery, Paul

    Published in Rheumatology (Oxford, England) (24-04-2024)
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: